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Abstract The aim of this study was to improve the neuro-
pathologic recognition and provide criteria for the patho-
logical diagnosis in the neurodegenerative diseases grouped
as frontotemporal lobar degeneration (FTLD); revised cri-
teria are proposed. Recent advances in molecular genetics,
biochemistry, and neuropathology of FTLD prompted the
Midwest Consortium for Frontotemporal Lobar Degeneration
and experts at other centers to review and revise the exist-
ing neuropathologic diagnostic criteria for FTLD. The pro-
posed criteria for FTLD are based on existing criteria,
which include the tauopathies [FTLD with Pick bodies,
corticobasal degeneration, progressive supranuclear palsy,
sporadic multiple system tauopathy with dementia, argyro-
philic grain disease, neuroWbrillary tangle dementia, and
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6 Acta Neuropathol (2007) 114:5–22FTD with microtubule-associated tau (MAPT) gene mutation,
also called FTD with parkinsonism linked to chromosome
17 (FTDP-17)]. The proposed criteria take into account
new disease entities and include the novel molecular
pathology, TDP-43 proteinopathy, now recognized to be
the most frequent histological Wnding in FTLD. TDP-43 is
a major component of the pathologic inclusions of most
sporadic and familial cases of FTLD with ubiquitin-posi-
tive, tau-negative inclusions (FTLD-U) with or without
motor neuron disease (MND). Molecular genetic studies of
familial cases of FTLD-U have shown that mutations in the
progranulin (PGRN) gene are a major genetic cause of
FTLD-U. Mutations in valosin-containing protein (VCP)
gene are present in rare familial forms of FTD, and some
families with FTD and/or MND have been linked to chro-
mosome 9p, and both are types of FTLD-U. Thus, familial
TDP-43 proteinopathy is associated with defects in multi-
ple genes, and molecular genetics is required in these cases
to correctly identify the causative gene defect. In addition
to genetic heterogeneity amongst the TDP-43 proteinopa-
thies, there is also neuropathologic heterogeneity and there
is a close relationship between genotype and FTLD-U sub-
type. In addition to these recent signiWcant advances in the
neuropathology of FTLD-U, novel FTLD entities have
been further characterized, including neuronal intermediate
Wlament inclusion disease. The proposed criteria incorpo-
rate up-to-date neuropathology of FTLD in the light of
recent immunohistochemical, biochemical, and genetic
advances. These criteria will be of value to the practicing
neuropathologist and provide a foundation for clinical,
clinico-pathologic, mechanistic studies and in vivo models
of pathogenesis of FTLD.
Keywords Frontotemporal dementia · Semantic dementia · 
Progressive non-Xuent aphasia · Frontotemporal lobar 
degeneration · Motor neuron disease · Tauopathy · 
Ubiquitin · TDP-43 proteinopathy · Progranulin · 
Valosin-containing protein · Charged multivesicular body 
protein 2B · Neuronal intermediate Wlament inclusion 
disease · Neuropathologic diagnosis
Introduction
In this paper, we follow the convention that FTLD is an
umbrella term that groups several diVerent neurodegenera-
tive diseases characterized by predominant destruction of the
frontal and temporal lobes. After Alzheimer disease (AD)
and dementia with Lewy bodies (DLB), frontotemporal
lobar degeneration (FTLD) is the third most common neuro-
degenerative cause of dementia in industrialized countries
[59, 60, 69]. Most commonly, patients with FTLD present
with frontotemporal dementia (FTD), a change in personal
and social conduct, often associated with disinhibition, with
gradual and progressive changes in language [53]. Other
patients falling under the diagnostic umbrella of FTLD may
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Acta Neuropathol (2007) 114:5–22 7present with early and progressive changes in language func-
tion, and two syndromes have been recognized: semantic
dementia (SD) and primary progressive non-Xuent aphasia
(PNFA) [40, 43, 53, 65, 67, 78]. In later stages of these par-
ticular syndromes, both behavioral and language dysfunction
may be present. A proportion of patients with FTLD present
with or develop parkinsonism as part of their disease pro-
cess. Clinical amyotrophic lateral sclerosis/motor neuron
disease (ALS/MND) may also be found in a proportion of
patients with FTLD, especially those with FTD, indicating a
spectrum of clinical phenotypes that relate to common neu-
ropathologic lesions [3, 61, 69].
FTD, SD, or PNFA refer to the main clinical syndromes
linked to the FTLD group. Typically, at least in the early
course of the disease, patients with FTD do not have an
amnestic syndrome, which distinguishes them clinically
from AD [46, 53], but there are exceptions [29]. Although
no pre-symptomatic biomarkers have been identiWed, at
least in sporadic cases, clinical assessment, neuropsychol-
ogy, and neuroimaging may help to distinguish FTD and
the related disorders of SD and PNFA from other neurode-
generative causes of dementia [12, 43, 46]. The diagnosis
of FTD, SD, or PNFA may only be considered when other
potential causes of dementia including other nervous sys-
tem diseases (e.g., small and large vessel disease), systemic
conditions (e.g., hypothyroidism), tumors, and substance
abuse have been excluded.
The apolipoprotein E (APOE) gene 4 allele is a major
risk factor for AD, though this is not the case in most asso-
ciation studies of FTLD (but see ref. [71]), and none of the
autosomal dominant mutations in genes associated with
some familial cases of AD [amyloid precursor protein
(APP), presenilin 1 (PS1) and presenilin 2 (PS2)] acts as a
risk factor for FTLD.
Recent developments in the molecular pathology and
genetics of FTLD now dictate that a minimal panel of patho-
logical investigations is required for correct diagnosis in this
group of diseases. Standardization of nomenclature and
approach will facilitate better understanding of clinico-patho-
logic correlations, provide insights into pathogenesis, and
guide the construction and validation of in vivo models.
Neuropathologic evaluation
With the exception of those cases in which a gene defect has
been identiWed, examination of the brain and neuropathology
are essential in order to determine the disease entity underly-
ing FTLD. Even in those cases that have been genetically
characterized, it is not uncommon to Wnd coexisting neuro-
degenerative disease and other pathology, which may have
contributed to the clinical picture to a varying degree. The
neuropathology of the brain, either on autopsy or, rarely, on
biopsy, remains the “gold standard” for determining the
neuropathologic diagnosis. Although most cases seen by a
neuropathologist are likely to be cases of advanced disease,
there is an increasing awareness that the molecular pathol-
ogy of all neurodegenerative disease is present often several
years prior to the onset of clinical symptoms, and this knowl-
edge will inform the neuropathologist of pre-clinical FTLD
in an otherwise cognitively and behaviorally normal subject.
Macroscopy
Examination of the brain of a patient with FTLD typically
shows symmetrical focal atrophy of the frontal or temporal
lobes, or both. In some patients there is asymmetry of atro-
phy, typically reXected in perisylvian loss on one side of
the brain. Macroscopic atrophy of the basal ganglia and
loss of pigmentation from the substantia nigra are seen in a
proportion of cases. This focal atrophy is, not infrequently,
the most dramatic in all of neuropathology. Conversely, in
some individuals, for example, those who die at an earlier
stage, the brain is unremarkable. The pattern of atrophy
may assist in staging disease severity [11, 39, 41].
Microscopy
In most forms of FTLD, examination of the cerebral cortex
with H&E staining shows microvacuolation and neuronal
loss. In many cases, this is most evident around layer II of the
aVected cortical regions. In advanced cases, there is transcor-
tical microvacuolation and neuronal loss. Swollen cortical
neurons may be seen and highlighted with immunostaining
for alpha B-crystallin; however, they are not speciWc for any
disease subtype. White matter myelin loss and astrocytic
gliosis may be seen. There may be signiWcant neuronal loss
from the basal ganglia and substantia nigra in some cases.
SpeciWc diagnosis of disease within the broad group of
FTLD now requires immunohistochemistry (IHC) to deter-
mine the molecular pathology, morphology, and distribution
of lesions in the neuraxis, and thereby identify the neurode-
generative disease. In the routine microscopic evaluation of
the brain of a patient with FTLD, other neurodegenerative
diseases may be identiWed, most commonly AD [18], DLB
[52], and, rarely, prion disease [33] and hereditary diVuse
leukoencephalopathy with axonal spheroids [76].
Although some neurodegenerative diseases can be readily
identiWed using conventional staining techniques (e.g., modi-
Wed Bielschowsky and Gallyas silver impregnations and thio-
Xavine-S for AD pathology [8, 18, 54]), more sensitive and
reliable IHC techniques are now preferred. IHC methods are
more consistent and dependable than are silver impregnation
techniques, they have greater inter-rater reliability, as shown
by the BrainNet Europe Consortium study [1], and IHC
results can suggest or identify underlying molecular pathology.123
8 Acta Neuropathol (2007) 114:5–22For example, antibodies raised against epitopes of tau readily
label the neuroWbrillary tangles, neuritic plaques, and neuro-
pil threads of AD; anti--amyloid antibodies detect diVuse
and compact -amyloid deposits and cerebral amyloid angi-
opathy [10]; while anti--synuclein antibodies label Lewy
bodies and Lewy neurites, the signature lesions of DLB [10,
52]. Neuropathologic staging schemes have been developed
using tau, -amyloid and -synuclein IHC, and IHC is now
replacing conventional stains in the neuropathologic diagnos-
tic criteria for AD and DLB [10, 18, 52]. Prion IHC may be
used reliably to detect or exclude prion disease in most cases
[33]. Proteins targeted for degradation are ubiquitinated and
several hallmark inclusions in neurodegenerative disease
either in neurons or glia or both are detected by ubiquitin
IHC [17, 19, 47, 48]. There is also age-related accumulation
of ubiquitinated material in the brain [23], which can make
detection of certain ubiquitin-related pathologies diYcult.
Until recently, ubiquitin IHC was the only marker for certain
neuronal inclusions seen in FTLD and ALS/MND that con-
tained neither tau nor -synuclein epitopes. P62 (sequesto-
some-1) IHC has recently been highlighted as an alternative
method to detect a range of ubiquitin-immunoreactive struc-
tures in neurodegenerative diseases including ALS/MND,
and FTLD. Like ubiquitin IHC, a range of pathological and
age-related abnormalities are detected, but an advantage over
anti-ubiquitin IHC appears to be that there is better contrast
in the detection of intracellular pathology. More recently,
TDP-43 has been identiWed as a major component of the
inclusions of FTLD with ubiquitin-positive, tau- and -syn-
uclein-negative inclusions (FTLD-U) [3, 61], formerly called
FTLD with MND-type inclusions, but without MND [53].
This protein now deWnes a novel class of neurodegenerative
diseases collectively called TDP-43 proteinopathies [16], and
TDP-43 IHC may be used to characterize a majority of
FTLD-Us, but not all [16].
Although IHC is essential for determining the underlying
molecular pathology of the majority of neurodegenerative
diseases, other techniques may be available in dementia
research centers and complement the routine neuropathologic
diagnosis. The reliable and robust detection of abnormally
aggregated proteins either within neurons or glia or both, or
in the neuropil, is necessary for neuropathologic diagnosis.
However, the density and distribution of abnormal protein
aggregates, as identiWed by IHC, do not always correlate well
with clinical symptoms. Other markers, such as synaptic and
neuronal loss in aVected brain areas, may correlate better
with cognitive impairment and motor dysfunction. Thus,
stereologic methods that assess synaptic and neuronal loss in
an unbiased manner may be useful in clinico-pathologic stud-
ies in the dementia research center, but are not necessary, or
usually feasible, for routine neuropathologic diagnosis.
Biochemistry is also useful, but not essential for diagnosis.
Methods of fractionating brain homogenates may be used
to rationally classify the tauopathies in a research setting
[13]. In the adult brain, there are normally six isoforms of the
microtubule-associated protein tau (MAPT): three isoforms
with 0, 1, or 2 inserts contain three microtubule-binding
repeats (3R tau) and three isoforms, also with 0, 1, or 2
inserts, contain four microtubule-binding repeats (4R tau)
[28]. The tauopathies have a biochemical signature: tau pro-
tein in these disorders is relatively insoluble and these insol-
uble species can be detected by biochemical fractionation
methods. The insoluble fractions may be further character-
ized according to the pattern of tau isoforms. For example, in
AD, all six isoforms are abnormally hyperphosphorylated
and migrate as three major bands and one minor band when
visualized by immunoblotting. Treatment with the enzyme
alkaline phosphatase removes phosphate groups, and the tau
isoforms appear as six bands (3R and 4R tau). This biochem-
ical signature may be used to distinguish AD from the FTLD
tauopathies [13]. Thus, brain tissue from patients with FTLD
where Pick bodies are present is characterized biochemically
by predominantly 3R tau, while CBD, PSP, argyrophilic
grain disease (AGD), and sporadic multiple system tauopa-
thy with dementia (MSTD) are predominantly 4R tauopa-
thies [13, 74], and neuroWbrillary tangle dementia (NTD),
also called tangle predominant form of senile dementia, has
inclusions containing a mixture of 3R and 4R tau [34, 35].
FTLD with MAPT mutation, of which more than 40 have
been described, is biochemically heterogeneous with diVer-
ent mutations being associated with 3R, 4R, or 3R and 4R
tauopathy [15]. Monoclonal antibodies, which discriminate
between 3R and 4R tau [22] are now commercially avail-
able; so, the molecular classiWcation of tauopathies by isoform
type may be easily undertaken in the histology laboratory
that does not have access to biochemistry.
FTLD with ubiquitin-positive, tau-negative inclusions
(FTLD-U), also known as FTLD with MND-type inclu-
sions or MND inclusion dementia, is the most common
underlying pathology in FTLD with and without clinical
MND [45, 73]. TAR DNA-binding protein 43 (TDP-43), a
nuclear protein implicated in exon skipping and transcrip-
tion regulation, was recently identiWed as a major protein
component of the ubiquitin-immunoreactive inclusions
characteristic of sporadic and familial FTLD-U, with and
without clinical MND, as well as in sporadic ALS [3, 16,
21, 61]. Biochemistry in these disorders shows TDP-43 to
be abnormally phosphorylated, ubiquitinated and cleaved to
generate C-terminal fragments, and is recovered only from
areas with ubiquitin-immunoreactive inclusions including
hippocampus, neocortex, and spinal cord [61]. The neuro-
pathology of these conditions is characterized by ubiquitin-
and TDP-43-positive neuronal cytoplasmic inclusions
(NCIs), neuronal intranuclear inclusions (NIIs), dystrophic
neurites (DNs), and glial cytoplasmic inclusions (GCIs)
that are negative for tau, -synuclein, -amyloid, neuronal123
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[21, 61]. The variability in the morphologic types of neuro-
nal inclusions, their distribution, density, and immunohisto-
chemical proWle has led to the proposed classiWcation
of FTLD-U into four pathologic subtypes [16, 63, 66].
Recently, mutations in the progranulin (PGRN) gene [4,
20, 57], the molecular genetic basis of non-tau familial
FTD linked to chromosome 17, were discovered. The neu-
ropathology in these cases is FTLD-U with ubiquitin-posi-
tive neurites, NCIs and, most characteristically, NIIs [4, 50]
(but see ref. [37]). However, NIIs can be seen in other
FTLD-U cases where PGRN mutations are not found [16]
and therefore such NIIs cannot be considered pathogno-
monic for PGRN or other (i.e., valosin-containing protein
VCP) mutations associated with FTLD. As demonstrated
by IHC and biochemistry, the ubiquitinated pathologic pro-
tein in these cases is not progranulin, but TDP-43 [4, 57].
Pathologic TDP-43 is detected biochemically in both
aVected gray and white matter, suggesting that both glial
and neuronal pathology may contribute to the pathogenesis
of FTLD-U caused by PGRN mutations [61].
Frontotemporal lobar degeneration with VCP gene muta-
tion, also called inclusion body myopathy associated with
Paget’s disease of bone and frontotemporal dementia
(IBMPFD), is a rare autosomal dominant disorder caused by
mutations in the VCP gene [77]. VCP, a member of the
AAA-ATPase gene super family (ATPase associated with
diverse cellular activities), has multiple cellular functions
including acting as a molecular chaperone in endoplasmic
reticulum-associated protein degradation, stress response,
programmed cell death, and interactions with the ubiquitin-
proteasome system. The neuropathology in FTLD with VCP
mutation is a unique subtype of FTLD-U and is characterized
by numerous NIIs and relatively few NCIs and DNs [26]; the
ubiquitinated inclusions are not primarily composed of the
mutated protein (VCP), but rather TDP-43 [26, 63].
Frontotemporal lobar degeneration with charged mul-
tivesicular body protein 2B (CHMP2B) gene mutation is
the cause of FTD linked to chromosome 3 in a large Danish
pedigree [68]. Human CHMP2B is a component of the
endosomal secretory complex, which becomes dysregu-
lated by the gene defects. Recent studies have revealed
ubiquitin-positive, but TDP-43 negative, NCIs in the fron-
tal neocortex and hippocampus, so that this disease is an
FTLD-U, but not a TDP-43, proteinopathy [16].
A genetic locus on chromosome 9p for familial FTD-
MND has been described [56]. In one family, candidate
gene sequencing revealed the presence of a putative disease
segregating stop codon mutation (Q342X) in the intraXagel-
lar transport protein 74 (IFT74) gene [55]. IFT74 is a pro-
tein that localizes to the intracellular vesicle compartment
and is a component of the intraXagellar transport system
responsible for vesicular transport of material synthesized
within the cell body into and along dendrites and axons.
Neuropathology in a single case with the IFT74 mutation
was reported as showing all the stigmata of FTLD-U (ubiq-
uitinated NCIs, DNs, and NIIs) and TDP-43 proteinopathy
similar to that seen in other reported families with FTD,
with or without MND linked to chromosome 9p [16]. None-
theless, it remains to be established in other families and
patients that IFT74 is indeed a true locus for FTLD.
Neuropathologic classiWcation of FTLDs
Following the principles of the previous consensus criteria
for the neuropathologic diagnosis of FTLD [53], and the
consensus criteria for the postmortem diagnosis of AD [18]
and DLB [52], we acknowledge that only probabilistic
statements can be made as to the causal relationship
between the neuropathology and the clinical phenotype.
Just as the constellation of clinical symptoms associated
with FTD, SD, or PNFA do not predict reliably the under-
lying causative neurodegenerative disease, the presence
of the neuropathology of FTLD does not predict with
certainty one or other of the clinical phenotypes associated
with FTLD, or even if the subject was demented. Small
series of cases are inadequate to reliably and robustly deter-
mine clinico-pathologic correlations with any one form of
FTLD. Multi-center collaborations are beginning to address
this challenge [25], and it is only by pooling relatively rare
cases from several research centers that reliable clinico-
pathologic correlations are likely to emerge.
The neuropathologic criteria proposed here (Table 1) are
an evolution of the 2001 criteria proposed by McKhann
et al. [53], and take into account more recent descriptions of
novel disease entities [6, 14], the discovery of causative
gene defects (PGRN, VCP, CHMP2B) and linkage to chro-
mosome 9p [4, 5, 20, 55, 56, 57, 68, 75, 77], and the novel
(TDP-43) proteinopathy, which is present in most cases of
FTLD-U with or without MND [3, 16, 21, 61]. The neuropa-
thologic diagnosis of FTLD requires the exclusion of other
neurodegenerative and systemic diseases, tumors, and drugs
of abuse, which may cause a clinical FTLD phenotype. The
proposed rational classiWcation of neurodegenerative dis-
eases associated with a clinical FTLD phenotype comprises
seven distinct neurohistological types, and is based on the
underlying molecular pathology as far as it is known.
Algorithm for the neuropathologic diagnosis of FTLD
The proposed criteria for the neuropathologic diagnosis and
nosology of FTLD builds on, and extends, the existing cri-
teria to include neuropathologic assessment using disease-
speciWc antibodies, biochemistry, and molecular genetics to123
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Present criteria McKhann et al. criteria
1. Tauopathy (with associated neuron loss and gliosis) and insoluble 
tau with a predominance of 3R tau, the most likely diagnoses are:
1. When the predominant neuropathological abnormalities 
are tau-positive inclusions (with associated neuron 
loss and gliosis) and insoluble tau has a predominance of 
tau with three microtubule-binding repeats, the most likely 
diagnoses are:
FTLD with Pick bodies (a) Pick disease
FTLD with MAPT mutation (b) Frontotemporal dementia with parkinsonism linked 
to chromosome 17
(c) Other as yet unidentiWed familial and sporadic 
frontotemporal disorders
2. Tauopathy (with associated neuron loss and gliosis) and insoluble tau 
with a predominance of 4R tau, the most likely diagnoses are:
2. When the predominant neuropathological abnormalities 
are tau-positive inclusions (with associated neuron 
loss and gliosis) and insoluble tau has a predominance 
of four microtubule-binding repeats, the most 
likely diagnoses are:
Corticobasal degeneration (a) Corticobasal degeneration
Progressive supranuclear palsy (b) Progressive supranuclear palsy
Argyrophilic grain disease (c) Frontotemporal dementia with parkinsonism linked 
to chromosome 17
Sporadic multiple system tauopathy with dementia (d) Other as yet unidentiWed familial and sporadic 
frontotemporal disordersFTLD with MAPT mutation
3. Tauopathy (with associated neuron loss and gliosis) and insoluble tau, 
with a predominance of 3R and 4R tau, the most likely diagnoses are:
3. When the predominant neuropathological abnormalities 
are tau-positive inclusions (with associated neuron loss 
and gliosis) and insoluble tau has a predominance of 
three and four microtubule-binding repeats, the most 
likely diagnoses are:
NeuroWbrillary tangle dementia (a) NeuroWbrillary tangle dementia
FTLD with MAPT mutation (b) Frontotemporal dementia with parkinsonism linked 
to chromosome 17
(c) Other as yet unidentiWed familial and sporadic 
frontotemporal disorders
4. Frontotemporal neuronal loss and gliosis without 
tau- or ubiquitin/P62-positive inclusions, 
the most likely diagnosis is:
4. When the predominant neuropathological abnormalities 
are frontotemporal neuronal loss and gliosis without 
tau- or ubiquitin-positive inclusions and without detectable 
amounts of insoluble tau, the most likely diagnoses are:
FTLD (also known as dementia lacking distinctive histologic features) (a) Frontotemporal lobar degeneration (also known as dementia 
lacking distinct histopathological features)
(b) Other as yet unidentiWed familial and sporadic 
frontotemporal disorders
5. TDP-43 proteinopathy with associated neuronal loss and 
ubiquitin-positive/P62-positive, tau-negative inclusions, 
with MND or without MND but with MND-type inclusions, 
the most likely diagnoses are:
5. When the predominant neuropathological abnormalities 
are frontotemporal neuronal loss and gliosis with 
ubiquitin-positive, tau-negative inclusions and without 
detectable amounts of insoluble tau, with MND or without 
MND but with MND-type inclusions, 
the most likely diagnoses are:
FTLD-U with MND (FTLD-U types 1–3) (a) Frontotemporal lobar degeneration with MND
FTLD-U but without MND (FTLD-U types 1–3) (b) Frontotemporal lobar degeneration with 
MND-type inclusions but without MND, or
FTLD-U with PGRN mutation (FTLD-U type 3) (c) Other as yet unidentiWed familial and sporadic 
frontotemporal disorders.
FTLD-U with VCP mutation (FTLD-U type 4)
FTLD-U linked to chromosome 9p (FTLD-U type 2)
Other as yet unidentiWed TDP-43 proteinopathies123
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CHMP2B charged multivesicular body protein 2B gene, FTLD frontotemporal lobar degeneration, FTLD-U FTLD with ubiquitin-positive, tau-,
-synuclein-, TDP-43-, and neuronal intermediate Wlament protein-negative inclusions, MAPT microtubule-associated protein tau gene, MND
motor neuron disease, neuroWbrillary tangle dementia, also called tangle predominant form of senile dementia, PGRN progranulin gene, TDP-43
TAR DNA-binding protein 43, VCP valosin-containing protein gene
Present criteria McKhann et al. criteria
6. Frontotemporal neuronal loss and gliosis with ubiquitin-positive/P62-positive,
TDP-43- and tau-negative inclusions, the most likely diagnoses are:
FTLD-U with CHMP2B mutation
Basophilic inclusion body disease (BIBD)
Other as yet unidentiWed FTLD-U, non-TDP-43 proteinopathies
7. Frontotemporal neuronal loss and gliosis with ubiquitin/P62 
and -internexin-positive inclusions, the most likely diagnosis is:
Neuronal intermediate Wlament inclusion disease (NIFID)
Fig. 1 Frontotemporal lobar degeneration neuropathology algorithm
Xow chart. AD Alzheimer’s disease, AGD argyrophilic grain disease,
AMYG amygdala, BIBD basophilic inclusion body disease, CBD
corticobasal degeneration, CBLM cerebellum including the dentate
nucleus (DN), CHMP2B charged multivesicular body protein 2B gene,
CG cingulate gyrus, DLB dementia with Lewy bodies, DLDH demen-
tia lacking distinctive histologic features, also called FTLD according
to McKhann et al. [4] criteria, FTLD frontotemporal lobar degenera-
tion, FTLD-U FTLD with ubiquitin-positive, tau-negative inclusions,
GP globus pallidus, H&E hematoxylin and eosin, HIP hippocampus,
IHC immunohistochemistry, INA -internexin, MAPT microtubule-
associated protein tau gene, MED medulla oblongata, MFG middle
frontal gyrus, MID midbrain including the substantia nigra, MND
motor neuron disease, MSTD sporadic multiple system tauopathy with
dementia, NIFID neuronal intermediate Wlament inclusion disease, NF
neuroWlament; neuroWbrillary tangle dementia, also called tangle pre-
dominant form of senile dementia, NOS not otherwise speciWed, OL
occipital lobe, PGRN progranulin gene, FL frontal lobe, PL parietal
lobe, PSP progressive supranuclear palsy, SC spinal cord, STG supe-
rior temporal gyrus, STR striatum, TDP-43 TAR DNA-binding protein
43, THAL/SUBTN thalamus and subthalamic nucleus, Ub ubiquitin,
VCP valosin-containing protein gene, 3R, 4R, or 3R and 4R tau
isoforms containing 3, 4, or 3 and 4 microtubule-binding repeats
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entities causing FTLD. It is appreciated that it may not be
practical, possible, or even necessary, to undertake sophisti-
cated neuroanatomical investigations of neuron and syn-
apse density, biochemistry or molecular genetics in every
case. For these reasons, the following neuropathologic
algorithm has been developed, which should be feasible at
most dementia research centers. It is envisaged that this
algorithm, with its inbuilt criteria for diagnosis, will super-
sede existing neuropathologic criteria [3], and become the
standard operational protocol for the working neuropatho-
logic diagnosis of FTLD (Figs. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
11, 12, 13, 14).
Recently, staging schemes have been developed that
no longer rely on capricious silver impregnation methods,
but employ instead sensitive monoclonal and polyclonal
Fig. 2 Frontotemporal lobar degeneration with Pick bodies. Pick
bodies (arrowheads) and a neuroWbrillary tangle (arrow) in the subic-
ulum (a) are immunolabeled by anti-phosphorylated tau antibodies
(PHF1 immunohistochemistry). Pick bodies are not immunolabeled
with anti-4R tau antibodies (arrowheads), while neuroWbrillary tangles
are immunolabeled (arrows) (b). Anti-3R tau antibodies clearly label
Pick bodies (arrowheads) (c). b 4R tau (ET3) and c 3R tau (RD3)
immunohistochemistry. Bars 10 m
Fig. 3 Corticobasal degenera-
tion. a A swollen achromatic 
neuron (arrow) in the middle 
frontal gyrus. Hematoxylin and 
eosin (HE). b Tau-positive 
neuroWbrillary tangles in the 
pyramidal neurons of the CA1 
hippocampal subWeld. c A 
globose neuroWbrillary tangle 
(arrow) in the locus coeruleus. 
d An astrocytic plaque 
(asterisk), coiled body (arrow), 
and threads (arrowhead) in the 
deep cortical laminae and white 
matter of the parietal lobe. b, c, d 
Anti-phosphorylated tau (PHF1) 
immunohistochemistry. Bars 
10 m123
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the major neurodegenerative diseases [9, 10, 52]. Multi-
center studies have conWrmed the reproducibility and reli-
ability of IHC over traditional staining methods, and IHC is
recommended for the detection of the signature lesions of
FTLD [1, 53], when appropriate. Thus, neurodegenerative
diseases with -synuclein pathology, with or without A
plaques and tau-positive neuroWbrillary tangle (AD) pathol-
ogy (i.e., DLB, Parkinson’s disease, and multiple system
atrophy), or those with plaque and tangle pathology (i.e.
Alzheimer disease) are excluded using established sam-
pling schemes and diagnostic criteria for these diseases [18,
52].
Tau-positive inclusions
Where neuroWbrillary tangles alone are present, in the
absence of A plaques, in the context of neuronal loss and
gliosis, NTD, also called tangle predominant form of senile
dementia, which, like AD tangles, contain tau composed
of all six isoforms, is a diagnostic possibility. Where the
distribution of neuronal and glial tau pathology is more
widespread and includes frontal, temporal, and parietal
neocortex, basal ganglia, and brainstem nuclei, then spo-
radic MSTD may be indicated [6]. NeuroWbrillary tangles
in more subcortical regions including the basal ganglia,
subthalamic nucleus, midbrain, and pontine nuclei indicate
progressive supranuclear palsy [31, 72]. Distinguishing
lesions in PSP are tau-positive tufted astrocytes and are
found in aVected neocortical and subcortical regions. Corti-
cobasal degeneration is characterized by frontal and tempo-
ral atrophy that is not infrequently asymmetric, neuronal
loss, gliosis, swollen achromatic neurons that are faintly
tau-positive, and tau-positive neuroWbrillary tangles in the
neocortex, basal ganglia, and brainstem nuclei [24, 27].
Distinguishing lesions in CBD are tau-positive astrocytic
plaques and threads found in the aVected neocortex and
subcortical white matter and in the basal ganglia. In both
PSP and CBD, tau-positive oligodendroglial inclusions
called coiled bodies are seen, but these are generally at a
lower density than inclusions in astrocytes. Tau-positive
ovoid structures (glial processes), astrocytes, and oligoden-
droglial inclusions (coiled bodies), when conWned to the
medial temporal lobe and limbic structures, indicate
another tauopathy, AGD [7]. If globose tau-positive NCIs,
called Pick bodies, are present in the non-pyramidal (den-
tate gyrus granule cells) and pyramidal neurons of area
CA1 of the hippocampus, and pyramidal neurons of the
temporal and frontal lobes, then FTLD with Pick bodies
may be present [80]. Pick bodies are largely or wholly com-
posed of 3R tau, which can be demonstrated by IHC or
immunoblotting, while the tau-positive inclusions of PSP,
CBD, MSTD, and AGD all contain 4R tau indicating that
these latter disorders may represent a spectrum of 4R tau-
opathies [13, 74]. Finally, FTLD with MAPT mutation, also
called FTD with parkinsonism linked to chromosome 17
(FTDP-17), is not only clinically and genetically heteroge-
neous (more than 40 mutations have been reported in the
MAPT gene), but is also neuropathologically heterogeneous.
The spectrum of neuronal and glial pathology seen in 3R,
4R, and combined 3R and 4R tauopathies is also found in
such cases of familial tauopathy [15, 44, 70]. For the prac-
ticing neuropathologist, the presence of this spectrum of
pathology in a case warrants further genetic investigation
particularly if there is an autosomal dominant pattern of
Fig. 4 Progressive supranuclear 
palsy. NeuroWbrillary tangles 
in the subthalamic nucleus (a), 
occulomotor nucleus (b), 
and locus coeruleus (e). 
Tufted astrocytes in the 
putamen (c and d). a, b, c, e 
Anti-phosphorylated tau (PHF1) 
immunohistochemistry. d Gallyas 
silver impregnation. Scale bars a 
50 m, b, c, d, e 10 m123
14 Acta Neuropathol (2007) 114:5–22inheritance. Similar 3R and 4R tau heterogeneity is seen in
some tauopathies that cannot be categorized as FTLD with
Pick bodies, PSP, CBD, or AGD, and in individuals without
MAPT mutations. Such a case may have tau pathology in the
distribution described in sporadic MSTD, or may have to be
categorized as “unclassiWable sporadic tauopathy.”
Fig. 5 Argyrophilic grain disease. A swollen achromatic neuron
(arrow) with pale center and more intense tau-immunoreactive
periphery in the subiculum. Tau-immunoreactive grains in the neuropil
and diVusely stained pyramidal neurons (arrow) indicating a pre-
neuroWbrillary tangle stage in the pyramidal layer of the hippocampus
(b). A tau-immunoreactive astrocytic inclusion (arrowhead) and
oligodendroglial cytoplasmic inclusions called coiled bodies (arrows)
in the CA1 subWeld of the hippocampus. (a, b, c) Anti-phosphorylated
tau (PHF1) immunohistochemistry. Scale bars (a) 100 m and (b and
c) 50 m
Fig. 6 Sporadic multiple system tauopathy with dementia. Neuronal
and glial globular inclusions at the gray/white junction. Anti-phos-
phorylated tau (PHF1) immunohistochemistry. Scale bar 100 m
Fig. 7 NeuroWbrillary tangle dementia. a, b Numerous neuroWbrillary
tangles in the upper and lower pyramidal neurons of the occipitotem-
poral cortex; no neuritic plaques or amyloid deposits are present.
a Gallyas silver impregnation. b Anti-phosphorylated tau (PHF1)
immunohistochemistry. Scale bars 50 m123
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TDP-43 proteinopathy
Immunohistochemistry for ubiquitin, P62, and TDP-43 in
cases with FTLD generally reveals similar pathology that
includes a spectrum of neuronal (NCIs, DNs, and NIIs) and
glial, predominantly oligodendroglial, cytoplasmic inclu-
sions (GCIs) [62, 61]. However, there are signiWcant diVer-
ences in the immunohistochemical Wndings with ubiquitin,
P62, and TDP-43. Ubiquitin immunoreactivity is present in
extensive age-related pathology in gray and white matter,
e.g., dot-like bodies and granular degeneration of myelin,
which can mask subtle neuronal and glial pathology and
can be diYcult to interpret. P62 immunostaining detects the
same range of pathological structures as anti-ubiquitin, but
highlights less age-related pathology, making interpretation
somewhat less demanding. TDP-43 immunoreactivity is
present in nuclei of most cells types and changes in distri-
bution within aVected neurons in disease. Screening cases
using TDP-43 immunostaining as a primary diagnostic
tool, as might be used for tau and -synuclein accumula-
tions, is more demanding. Four histologic subtypes of
FTLD-U have been proposed, based on the predominant
type of inclusion present as detected using anti-ubiquitin,
its distribution in the cortex, and density [16, 63, 66]. Other
types have been proposed as well and take into account
involvement of other brain regions (e.g., hippocampus or
corpus striatum) and the morphology of the lesions [2, 38].
Patterns of FTLD-U histology based solely on cortical
pathology include a system proposed by Sampathu et al.
[66], and Neumann et al. [63]; while Mackenzie et al. [49]
Fig. 8 Frontotemporal lobar degeneration (FTLD) with MAPT muta-
tion. Inclusions in FTLD with MAPT G389R mutation (a) and FTLD
with MAPT intron 10 + 16 mutation (b–g). a Numerous tau-immuno-
reactive Pick body-like inclusions in the granule neurons of the dentate
fascia. b A swollen achromatic neuron in the superior temporal gyrus.
c A swollen neuron with a central area of pale anti-tau immunoreactiv-
ity surrounded by more intense staining. Fibrillary material surrounds
the nucleus and extends into the apical dendrite. d An intraneuronal
inclusion resembling a Pick body in the superior frontal gyrus. e A neu-
roWbrillary tangle-like inclusion in layer V of the superior frontal gy-
rus. f A globose neuroWbrillary tangle-like inclusion in the dorsal raphé
nucleus. g An astrocytic Wbrillary inclusion (a) and a coiled body (b)
in an oligodendrocyte in the white matter of the frontal lobe. b Hema-
toxylin and eosin (HE); (a, c–g) anti-phosphorylated tau (AT8) immu-
nohistochemistry. Scale bars 10 m. (Adapted from Ref. [44];
reproduced with permission)123
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fascia inclusions. In all these schemes the same descriptors
were employed to diVerentiate subtypes, though the
numbering of each subtype diVered among schemes. In the
present composite scheme, type 1 cases (as in [66], but
known as type 2 in Mackenzie et al. [49]) are characterized
by an abundance of long DNs, predominantly in the superW-
cial cortical laminae, with few or no NCIs or NIIs. Type 2
cases (as in [66], but known as type 3 in Mackenzie et al.
[49]) are characterized by numerous NCIs in both superW-
cial and deep cortical laminae as well as infrequent DNs
and sparse or no NIIs. Type 3 cases (as in [66], but known
as type 1 in Mackenzie et al. [49]) are characterized by
pathology predominantly in the superWcial cortical layers
with numerous NCIs, DNs, and variable numbers of NIIs.
Type 4 cases [16, 63] are distinguished by numerous NIIs
and infrequent NCIs and DNs in the neocortical areas with
relative sparing of the hippocampus, consistent with the
pathology described in cases of FTLD with VCP mutations
(but see ref. [30]). Consensus on the validity, reliability,
and reproducibility of the various proposed typing schemes,
as well as their clinical signiWcance, remain to be deter-
mined.
If TDP-43- and ubiquitin- or P62-positive, tau- and -
synuclein-negative inclusions are found in the superWcial
laminae of the frontal and temporal neocortex and neurons
of the dentate gyrus, the most likely diagnosis is FTLD-U
[21, 36, 45]. If in addition, there is TDP-43 proteinopathy
and ubiquitin-positive inclusions in the lower motor neu-
rons and evidence of motor neuron loss, gliosis, Bunina
bodies, and corticospinal tract degeneration, FTLD with
MND is the most likely diagnosis [53, 64, 79].
Fig. 9 Frontotemporal lobar degeneration (FTLD)-U with or without
MND: spectrum of TDP-43 pathology. Adjacent sections of superWcial
frontal neocortex showing neuronal cytoplasmic inclusions (NCIs),
dystrophic neurites (DNs), and isolated neuronal intranuclear inclu-
sions (NIIs) stain for both ubiquitin (a) and TDP-43 (b). NCI in the
dentate granule cells stain for ubiquitin (c) and TDP-43 (d). Neuronal
and glial inclusions include NCI (e), round and lentiform NIIs (f, g);
skein-like (h), and compact round (i) NCI in the lower motor neurons;
and glial cytoplasmic inclusion (GCI) (j). (a and c) ubiquitin immuno-
histochemisty (b, d, e–j TDP-43 immunohistochemistry). Scale bars
10 m (a–d); 5 m (e–j) (Adapted from Ref. [16]; reproduced with
permission)
Fig. 10 Frontotemporal lobar degeneration-U with MND. DiVuse
perinuclear staining in a motor neuron (arrow). TDP-43 immunohisto-
chemistry. Scale bar 10 m123
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FTLD-U beyond pathologic description alone, with clinical
and genetic correlates of histologic patterns emerging.
Cases with type 1 histology are associated with SD,
whereas cases of FTLD with MND frequently show type 2
histology [49]. In genetic terms, cases with PGRN or VCP
gene mutations, and in cases linked to chromosome 9, dis-
tinct patterns of ubiquitin- and TDP-43-positive inclusions
are also seen. FTLD with PGRN mutation cases often dis-
play a PNFA clinical phenotype and exclusively show type
3 histology [16], whereas those with VCP mutations have
type 4 histology. Cases linked to chromosome 9 have type
2 histology [16] and the majority of such cases also have
ubiquitin- and TDP-positive inclusions in the upper and
lower motor neurons, identical to those encountered in
sporadic MND [16] or sporadic FTLD with MND where a
similar type 2 histology is often present [49]. These latter
data indicate that the pathology of FTLD linked to chromo-
some 9p is a speciWc subtype of FTLD-U (type 2) and that
TDP-43 is the disease-associated protein. Biochemistry of
sporadic cases of FTLD with and without MND, cases of
sporadic ALS, and familial cases of FTLD-U with PGRN
and VCP mutations, and those linked to chromosome 9p,
all have a characteristic biochemical signature: TDP-43 is
detected in the detergent-insoluble urea fractions from
aVected regions and is abnormally phosphorylated, with
additional protein bands of »25 and 45 kDa, as well as a
high molecular smear, and is ubiquitinated [16, 61, 62, 63].
The quantity of these modiWed TDP-43 species detected by
biochemistry [62, 63] may be variable, but correlates with
the amount of pathology detected by IHC. Additionally, the
45 kDa species collapse into a 43 kDa band upon dephos-
phorylation with alkaline phosphatase, indicating that TDP-
43 is abnormally phosphorylated, with features paralleling
the biochemical changes seen in the tauopathies. Hippo-
campal sclerosis (HS) may be found as a coexisting pathol-
ogy in FTLD-U with or without MND, and small numbers
of ubiquitin- and TDP-43-positive inclusions may be seen
exclusively in the dentate granule cells. Preliminary data
indicate that some, or perhaps most, cases of HS are TDP-
43 proteinopathies [2], but further studies on larger samples
of “pure HS” and biochemical studies are required to deter-
mine the nosologic status of HS.
TDP-43-negative inclusions
In those cases that have ubiquitin- or P62-positive, TDP-
43-, tau-, and -internexin-negative NCIs in the frontal
and temporal lobes and dentate gyrus, the most likely
diagnosis is FTLD with CHMP2B mutation [16]. Muta-
tions in the CHMP2B gene are the cause of FTD-linked
to chromosome 3 in a large Danish pedigree [68]. Human
CHMP2B is a component of the endosomal secretory
complex, which becomes dysregulated by the gene defect.
However, the absence of DN and the presence of granular,
ubiquitin-positive structures within the neocortex of these
cases distinguish this FTLD-U subtype from the types 1–4
described above. Thus, based on the small number of
cases studied to date, familial FTLD with CHMP2B muta-
tion appears to be a distinctive pathologic subtype of
FTLD-U and is not a TDP-43 proteinopathy on the basis
of IHC.
In cases of FTLD where there is frontotemporal neuron
loss and gliosis, -internexin- or neuroWlament-positive,
TDP-43-, -synuclein-, and tau-negative, and variably
ubiquitinated but P62-positive neuronal inclusions, the
most likely diagnosis is neuronal intermediate Wlament
inclusion disease [14]. Where there is FTLD and P62-positive,
Fig. 11 Frontotemporal lobar 
degeneration-U, subtypes 1–4. 
a–d Type 1 is characterized by 
long and tortuous dystrophic 
neurites (DNs) in lamiae II/III 
with relatively few neuronal 
cytoplasmic inclusions (NCIs) 
and no neuronal intranuclear 
inclusion (NII). b Type 2 has 
numerous NCIs, relatively few 
DNs, and no NII is present. 
c Type 3 has numerous NCIs 
and DNs and an occasional NII 
in lamina II. d Type 4 pathology 
in a case of FTD with VCP 
mutation is characterized by 
numerous NII and DN, but few 
NCI. TDP-43 
immunohistochemistry. Scale 
bar 10 m (a–d). (Adapted from 
Ref. [14]; reproduced with 
permission)123
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uclein-, and tau-negative basophilic inclusions, the most
likely neuropathologic diagnosis is basophilic inclusion
body disease (BIBD) [58]. If all of the antibodies listed
above and routine histological stains such as hematoxylin
and eosin fail to reveal signature lesions, and if prion dis-
ease has been excluded by IHC or molecular genetics, the
remaining FTLD diagnosis is dementia lacking distinctive
histologic features (DLDH) [42]. However, it should be
borne in mind that in many of the earlier histopathologic
surveys, a relatively high proportion of cases of DLDH
were encountered [32, 67]. Re-evaluation of such cases
using either more sensitive ubiquitin IHC methodologies
Fig. 12 Frontotemporal lobar degeneration with CHMP2B mutation.
a Sparse ubiquitin-immunoreactive NCIs (arrows) in the granule neu-
rons of the dentate fascia. The NCIs are not labeled with anti-TDP-43
antibodies (b). Ubiquitin-positive neuropil aggregates and a sparse
NCI (arrow) in the frontal lobe of an aVected 61-year-old female (c).
Scale bars a, b 50 m, c 10 m
Fig. 13 Basophilic inclusion body disease. a A basophilic inclusion
(BI) in the precentral gyrus (motor cortex), with a similar, weakly
ubiquitin-immunoreactive inclusion in (b). c Neurons with basophilic
inclusions showing Wne granular perikaryal TDP-43 positivity in neu-
rons with BIs on the left and negative in neurons with BIs on the right.
a Hematoxylin and eosin; b ubiquitin, and c TDP-43 immunohisto-
chemistry. Scale bars 20 m123
Acta Neuropathol (2007) 114:5–22 19[25, 45, 51] or TDP-43 IHC [21] shows DLDH to be an
uncommon cause of FTLD and, indeed, it still remains to
be proven as a discrete entity with diagnostic criteria other
than default characteristics being employed when all IHC
and other methods have failed to reveal signature lesions.
Conclusions
The proposed criteria for the neuropathologic diagnosis of
FTLD described here are an evolution of the previous crite-
ria described by McKhann et al. [53]. When formulating
these proposed criteria, we acknowledged revised staging
schemes for other disorders (e.g., AD and DLB), which rec-
ommend the use of IHC for the diagnosis of neurodegener-
ative diseases, replacing silver impregnation methods and
averting the lack of reproducibility between centers when
these stains are used. We have incorporated the recent iden-
tiWcation of new entities into the nosology of FTLD. Most
signiWcantly, the discovery of TDP-43 as the major patho-
logic protein of most forms of FTLD identiWes a novel
molecular pathology, TDP-43 proteinopathy, and this is
now included in the revised criteria. We have also consid-
ered the great progress in determining the molecular genet-
ics of FTLD. In addition to FTLD with MAPT mutation,
other familial subtypes are now recognized on the basis of
the neuropathology of ubiquitin and/or TDP-43 IHC,
biochemistry, and molecular genetics (FTLD with PGRN,
CHMP2B, and VCP mutations, and cases linked to chromo-
some 9p), which reveal a strong correlation between
genotype and neuropathologic phenotype. To facilitate
neuropathologic diagnoses of FTLD at research and other
centers, commercially available antibodies are now readily
available for the identiWcation of the underlying molecular
pathologies (e.g., TDP-43 proteinopathy and tauopathy)
and the rational diagnosis and nosology of a case of FLTD
that comes to autopsy. The neuropathologic diagnostic
algorithm described here is based on the current level of
knowledge, but the consortium members appreciate that
further study of TDP-43 proteinopathy may reveal new
subtypes and that other FTLD entities may yet be identi-
Wed. The proposed neuropathologic algorithm will facilitate
eVorts to improve the diagnosis of FTLD and encourage
multi-center clinico-pathologic studies. Together, these
eVorts should improve the early and reliable neuropatho-
logic diagnosis of the FTLD, raise the awareness of possi-
ble coexisting pathologies, and facilitate research eVorts
into pathogenesis and potential treatments where none cur-
rently exists.
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